

Onset, characteristics, treatments, and burden of New Daily Persistent Headache: Initial data from the NDPH Patient Experience Survey

Alan Kaplan¹, Christina L. Szperka^{2,3}, Amy A. Gelfand⁴, Randolph W. Evans⁵, Matthew S. Robbins⁶, Celia K. Tran⁷, Kevin Lenaburg⁸, Mark J. Burish⁷

¹NDPHaware.org

^{2,3}Department of Neurology, University of Pennsylvania and Children's Hospital of Philadelphia

⁴Department of Neurology, University of California San Francisco

⁵Department of Neurology, Baylor College of Medicine, Houston, Texas

⁶Department of Neurology, Weill Cornell Medicine, New York

⁷Department of Neurosurgery, UTHealth Houston

⁸Clusterbusters, Inc.

Presenting Author: Mark Burish MD PhD

Neurologist and Headache Specialist

Associate Professor, Dept. of Neurosurgery

Director, Will Erwin Headache Research Center

mark.j.burish@uth.tmc.edu

 UTHealth[®] Houston

66th Annual
**Scientific
Meeting**

JUNE 13-16, 2024
SAN DIEGO, CA



Disclosures for Presenting Author

Research support

- Will Erwin Headache Research Foundation

Consultant

- Beckley Limited
- Lundbeck
- Puretech Health

Speaker's bureau


- None

Off-label use


- Yes, all treatments for NDPH are off-label

Survey information

A Inclusion/exclusion flow chart



B Validation interview flow chart



Validation results (n=34)

94% with NDPH


32 with NDPH

1 possible cervicogenic

1 started after stroke

Demographics


Sex assigned at birth




Age

41.2 ± 15.4 years
(range 13-84)

Race/ethnicity




Country of residence




Headache onset


Age of onset (in years), all sexes (n=336)




Age of onset (in years) for female (n=242) and male (n=93)



Possible triggering event in the 3 months before onset




Associated features



Acute treatment

Requirements: tried at least once, minimum 10 respondents, guideline-recommended doses



Abbreviations

Acetamin/butalb/caff: acetaminophen/butalbital/caffeine

DHE: dihydroergotamine

Isometh/dichlor/acetamin: isometheptene/dichloralphenazone/acetaminophen


nVNS: non-invasive vagus nerve stimulation

REN: remote electrical neuromodulation


tSNS: transcutaneous supraorbital nerve stimulation

Preventive treatment


Requirements: tried for 2 months (most treatments) or 3 months (CGRP + Onabotulinum Toxin A), minimum n=10 respondents, guideline-recommended doses




Disability, mood, sleep, and stigma




Anxiety (GAD7)




Sleep Disturbance (NeuroQol)



Depression (PHQ8)



Stigma (SSCI8)



Conclusions

- Onset peaks between 11-40 years of age
- The most common potential triggers are stressors and inflammation
- The most common associated feature is brain fog
- The most effective acute treatments are opioids
- The most effective preventive treatments are CGRP antagonists
- More than 4 in 5 respondents had severe disability

Thanks!

Authors: Alan Kaplan¹, Christina L. Szperka^{2,3}, Amy A. Gelfand⁴, Randolph W. Evans⁵, Matthew S. Robbins⁶, Celia K. Tran⁷, Kevin Lenaburg⁸, Mark J. Burish⁷

¹NDPHaware.org

^{2,3}Department of Neurology, University of Pennsylvania and Children's Hospital of Philadelphia

⁴Department of Neurology, University of California San Francisco

⁵Department of Neurology, Baylor College of Medicine, Houston, Texas

⁶Department of Neurology, Weill Cornell Medicine, New York

⁷Department of Neurosurgery, UTHealth Houston

⁸Clusterbusters, Inc.

mark.j.burish@uth.tmc.edu